Cariprazine shows encouraging results in treatment of bipolar depression

A double‐blind, placebo‐controlled Phase II study of the atypical antipsychotic cariprazine for the treatment of bipolar depression has found the most highly effective outcomes with a dose of 1.5 mg/day. A dose of 3 mg/day resulted in improvement in depressive symptoms, but results were not significant when adjusted for potential confounding factors. A dose of 0.75 mg/day did not result in improvement over placebo. Results were published online Nov. 6, 2015, in the American Journal of Psychiatry.
Source: The Brown University Psychopharmacology Update - Category: Psychiatry Tags: Bipolar Disorder Treatment Source Type: research